Opportunities in Non-Surgical Bio-Implants: Marketed Injectable Biomaterials, Applications, and Leading Players

Date: June 22, 2010
Pages: 94
Price:
US$ 3,835.00
Publisher: Business Insights
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: OF42F3B009DEN
Leaflet:

Download PDF Leaflet

Opportunities in Non-Surgical Bio-Implants: Marketed Injectable Biomaterials, Applications, and Leading Players
Injectable bio-implants provide rapid non-surgical treatments and offer effective replacement, restoration, or modulation of function to lost, damaged, or dysregulated physiology. Market opportunities for injectable bio-implants are high in an increasingly aging population that demands fast, effective, and safe treatments for age-related conditions. Both medical and aesthetic applications for biomaterials make the market opportunities for injectable bio-implants highly attractive for drug and device manufacturers. However, biocompatibility is crucial for any implantable biomaterial to integrate into the host anatomy and prevent an immunogenic response.

This report provides a comprehensive assessment and analysis of the current market for viscoaugmentation and viscosupplementation products and shows how research and development has expanded product choice and diversity among the relatively limited injectable medical devices that are approved.

The report also shows promising next-generation bio-implants and those in preclinical research and clinical development. It details the challenges of achieving biocompatibility and the technologies that have successfully emerged from biomaterials research. Additionally, the report details the major players, market opportunities, and emerging sectors of the field that are changing the landscape of injectable treatments with major applications in cosmetic dermatology and orthopedics. The report also shows how reformulation and product line extensions may be needed to succeed in an increasingly saturated market sector.

Key features of this report
  • Analysis of current biomaterials that have been developed as injectable medical devices
  • Evaluation of the barriers and problems associated with biocompatibility for developed biomaterial types
  • Identification of the current trends in injectable bio-implants for aesthetic and medical indications and how companies have expanded indications to increase revenues and portfolios
  • Analysis of next-generation products and how companies are reformulating products to improve clinical performance and patient attractiveness.
  • Assessment of approved injectable viscoaugmentation and viscosupplementation devices and the strategies employed to expand product lines

Scope of this report
  • Understanding of the key obstacles in research for biocompatibility in the development of injectable medical devices
  • Rationale for injectable device development and how biomaterials R&D has evolved to meet unmet needs in aesthetics and orthopedics
  • Up-to-date information on the marketed viscoaugmentation and viscosupplementation product sectors
  • Evaluates the key recent developments and activities of companies who are developing and licensing injectable bio-implant technologies.

Key Market Issues
  • Biocompatibility is a critical issue for commercial development of injectable bio-implants. Products that are not safe and biocompatible will fail in the marketplace.
  • Medical technology and device developers need to develop next-generation products that offer greater clinical benefits, value, and patient and physician preference.
  • Demand for more durable and adaptable formulations of bio-implants has led to expanded brands and indications in the market.
  • Reimbursement issues for injectable bio-implants in orthopedics is driving innovation to reformulate products that are more durable and hence more cost-effective.
  • Development efforts are underserved and focus on limited repertoire of biomaterials that reach the clinic.

Key findings from this report
  • Biocompatibility is a critical issue that challenges research and development of injectable bio-implants. Commercialized products are limited to collagens, hyaluronic acids, polymer formulations, and ceramics.
  • Demand for safer, more effective treatment options has stimulated R&D to produce a variety of same-type products differentiated by type, size, indication, and unmet needs mainly in cosmetic dermatology and orthopedics.
  • Commercial opportunities are evident for approved viscoaugmentation and viscosupplementation products in crossover fields where injectable bio-implants may be developed for a variety of diverse conditions.
  • Research and development themes are limited and few novel biomaterials have reached the clinic indicating upside potential for R&D in the field.
  • Companies are increasingly licensing and re-marketing products across therapeutic areas to maximize sales revenues, novelty, and product choice.

Key questions answered
  • What are key challenges in developing an injectable biomaterial and bio-implant?
  • What are the current commercialized product types and how have they evolved?
  • What are the key viscoaugmentation and viscosupplementation products and what key indications are they used for?
  • What are the trends in product development for approved injectable products?
  • How are companies optimizing their product lines?
Opportunities in Non-surgical Bio-implants Executive summary
Injectable biomaterials
Viscoaugmentation
Viscosupplementation
Alloplastic injectable biomaterials: R&D

CHAPTER 1 INJECTABLE BIOMATERIALS

Summary
Introduction
Development issues
Problems with biocompatibility
Design factors
Rationale for development of injectable biomaterials
Types of injectable biomaterials
Collagen
Hyaluronic acid
Hydrogels
Hydroxyapatite
Calcium phosphate ceramic pastes
Biopolymers
Adverse reactions associated with current injectable biomaterials
Ideal properties of injectable biomaterials

CHAPTER 2 VISCOAUGMENTATION

Summary
Soft tissue viscoaugmentation bio-implants
Trends in injectable cosmetic treatments in the US
Primary indications for soft-tissue augmentation products
Collagen
Companies, products, and market activities
Allergan’s Zyderm-Zyplast/Cosmoderm-Cosmoplast range
Recent industry activities: Evolence discontinued
Hyaluronic acid
Companies, products, and market activities
Adoderm
Allergan
Anteis
Anika Therapeutics
BioPolymer GmbH & Co. KG
Coapt Systems
Fidia Farmaceutici
KuhraVital Dermapharma
Laboratoires Filorga
L&M Aesthetic Equipment/Parpas Group
LCA Pharmaceutical
Hangzhou Gallop Biological Products
Novatex Bioengineering/Laboratoires Org?v
Johnson & Johnson/Mentor Corp.
Puragen
Merz Pharma/Merz Aesthetics
Q-Med
Nordic Aesthetics
Prollenium Medical Technologies
Rofil Medical/Philoderm Aesthetics
Teoxane Laboratoires
Biopolymers
Dimethicone/silicone oil
Companies, products, and market activities
Contura International
FzioMed
Polymekon
Suneva
ProCytech
Sanofi-Aventis
Generic polymeric soft tissue fillers
Ceramics/hybrid technologies
Companies, products, and market activities
BioForm Medical
Stiefel Laboratories/GlaxoSmithKline

CHAPTER 3 VISCOSUPPLEMENTATION

Summary
Intra-articular injectable bio-implants
Marketed injectable products and company activities
Anika Therapeutics
Anteis
BioPolymer
Curasan
Ferring Pharmaceuticals
Fidia Farmaceutici
Genzyme Corp
LCA Pharmaceutical
Novatex Bioengineering
Ortho Biotech/Johnson & Johnson/Anika Therapeutics
Q-Med/Smith & Nephew
Sanofi-Aventis
Seikagaku/Smith & Nephew
TRB Chemedica
Generic sodium hyaluronate

CHAPTER 4 ALLOPLASTIC INJECTABLEBIOMATERIALS: R&D

Summary
Alloplastic injectable biomaterials: current R&D
Viscoaugmentation: cosmetic applications
Albiorex
FibroGen
Kythera Pharmaceuticals
Moma Therapeutics
Novatex Bioengineering
Prollenium Medical Technologies
Viscosupplementation: medical/surgical applications
Anika Therapeutics
Barrow Neurological Institute at St. Joseph’s Hospital and Medical
Center, US
Biotechnology Institute IMASD
Genzyme Corp
Pioneer Surgical Technology
Prollenium Medical Technologies
Seikagaku
Considerations, insights, and recommendations
Appendix
Scope
Methodology
Glossary
Index

LIST OF FIGURES

Figure 1.1: Potential adverse responses to implanted biomaterials
Figure 1.2: Essential design components for biocompatibility of implantable biomaterials
Figure 1.3: Types of marketed injectable biomaterials
Figure 1.4: Medical applications and benefits of hydrogels
Figure 1.5: Potential adverse reactions associated with injectable biomaterials
Figure 2.6: Trends in injectable treatments in the US, 2003–2009
Figure 2.7: Primary indications for soft tissue dermal fillers

LIST OF TABLES

Table 1.1: Basic properties and medical applications of biomaterials
Table 1.2: Medical applications of hyaluronic acid
Table 1.3: Medical applications of biopolymers
Table 2.4: Marketed collagen-based injectable products
Table 2.5: Main indications for Allergan’s collagen-based injectable products
Table 2.6: Adoderm’s hyaluronic acid-based injectable products
Table 2.7: Allergan’s hyaluronic acid-based injectable products
Table 2.8: Anteis’ hyaluronic acid-based injectable products
Table 2.9: Anika Therapeutics’ hyaluronic acid-based injectable products
Table 2.10: Biopolymer’s marketed hyaluronic acid-based injectable products
Table 2.11: Coapt Systems’ marketed hyaluronic acid-based injectable products
Table 2.12: KuhraVital’s marketed hyaluronic acid-based injectable products
Table 2.13: Laboratoires Filorga’s marketed hyaluronic acid-based injectable products
Table 2.14: L&M Aesthetic’s marketed hyaluronic acid-based injectable products
Table 2.15: LCA Pharma’s marketed hyaluronic acid-based injectable products
Table 2.16: HGBP’s marketed hyaluronic acid-based injectable products
Table 2.17: Novatex’s hyaluronic acid-based injectable products
Table 2.18: J&J’s marketed hyaluronic acid-based injectable products
Table 2.19: Merz Pharma’s marketed hyaluronic acid-based injectable products
Table 2.20: Q-Med’s marketed hyaluronic acid-based injectable products
Table 2.21: Nordic Aesthetics’ marketed hyaluronic acid-based injectable products
Table 2.22: Prollenium’s marketed hyaluronic acid-based injectable products
Table 2.23: Rofil Medical/Philiderm Aesthetics’ marketed hyaluronic acid-based injectable products
Table 2.24: Teoxane’s marketed hyaluronic acid-based injectable products
Table 2.25: Contura’s marketed polymer-based injectable products
Table 2.26: FzioMed’s marketed polymer-based injectable products
Table 2.27: Polymekon’s marketed polymer-based injectable products
Table 2.28: Suneva’s marketed polymer-based injectable products
Table 2.29: ProCytech’s marketed polymer-based injectable products
Table 2.30: Sanofi-Aventis’ marketed polymer-based injectable products
Table 2.31: BioForm Medical’s injectable ceramic-based products
Table 2.32: Stiefel Laboratories/GSK’s injectable ceramic-based products
Table 3.33: Application of biomaterials for orthopedic applications
Table 4.34: Selected allosteric viscoaugmentation products in development
Table 4.35: Selected allosteric viscosupplementation products in development
Skip to top


Ask Your Question

Opportunities in Non-Surgical Bio-Implants: Marketed Injectable Biomaterials, Applications, and Leading Players
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: